Cargando…

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence

The burden and cost of heart failure management, primarily in the form of hospitalization in the setting of decompensated heart failure, continue to be some of the biggest clinical challenges in cardiovascular medicine. In recently published randomized controlled trials, including DAPA-HF, sodium-gl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Manasvi, Rao, Shiavax, Manek, Gaurav, Fonarow, Gregg C, Ghosh, Raktim K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367215/ https://www.ncbi.nlm.nih.gov/pubmed/34408424 http://dx.doi.org/10.2147/TCRM.S275076

Ejemplares similares

PREDICTING OUTCOMES IN COVID-19 PNEUMONIA WITH ACUTE RESPIRATORY FAILURE USING THE RESPIRATORY RATE-OXYGENATION INDEX
por: GUPTA, MANASVI, et al.
Publicado: (2021)

IMPACT OF ADMISSION TROPONIN AND TROPONIN RISE DURING HOSPITALIZATION ON MORTALITY IN COVID-19 PNEUMONIA WITH ACUTE RESPIRATORY FAILURE
por: GUPTA, MANASVI, et al.
Publicado: (2021)

Submassive Pulmonary Embolism in Mild COVID-19 Without Lung Infiltrates
por: Manek, Gaurav, et al.
Publicado: (2021)

CAN OUTCOMES IN PATIENTS WITH COVID-19 PNEUMONIA AND ACUTE RESPIRATORY BE PREDICTED WITH ADMISSION SERUM LACTIC ACID LEVELS?
por: NGUYEN, SUONG, et al.
Publicado: (2021)

Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes
por: Kaul, Subuhi, et al.
Publicado: (2020)

Current Status of Dapagliflozin in Congestive Heart Failure
por: Palandurkar, Gopal, et al.
Publicado: (2022)

Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
por: Tummala, Ramyashree, et al.
Publicado: (2022)

COVID-19 Pandemic: Cardiovascular Complications and Future Implications
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2020)

Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis
por: Hajra, Adrija, et al.
Publicado: (2021)

Correction to: Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis
por: Hajra, Adrija, et al.
Publicado: (2021)

Hemodynamic indices in pulmonary hypertension: a narrative review
por: Manek, Gaurav, et al.
Publicado: (2022)

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
por: Escobar, Carlos, et al.
Publicado: (2023)

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
por: Talha, Khawaja M., et al.
Publicado: (2022)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Dapagliflozin for heart failure according to body mass index: the DELIVER trial( )
por: Adamson, Carly, et al.
Publicado: (2022)

Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure
por: Nazer, Rakan, et al.
Publicado: (2022)

The effect of Dapagliflozin on renal functions in hospitalized patients with Acute Heart Failure
por: Gilani, Syedah Fauzia Fatima, et al.
Publicado: (2023)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
por: Serenelli, Matteo, et al.
Publicado: (2020)

Reply: Alternative Models of Cardiac Rehabilitation Delivery Urgently Needed to Improve Access for Heart Failure Patients
por: Keshvani, Neil, et al.
Publicado: (2021)

Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis
por: Cai, Ru-ping, et al.
Publicado: (2021)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
por: Wu, Meiyu, et al.
Publicado: (2022)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea
por: Jaffuel, Dany, et al.
Publicado: (2023)

Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
por: Ali, Ahmed E., et al.
Publicado: (2023)

Dapagliflozin-affected endothelial dysfunction and altered gut microbiota in mice with heart failure
por: Bao, Nandi, et al.
Publicado: (2023)

Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines–Heart Failure Registry
por: Cunningham, Luke C., et al.
Publicado: (2021)

HEALTHCARE UTILIZATION FOR US VETERANS WITH HEART FAILURE DURING THE COVID19 PANDEMIC
por: Brownell, Nicholas Keisuke, et al.
Publicado: (2023)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
por: Mendoza, Victor L., et al.
Publicado: (2021)

Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients
por: Wang, Chuanqiang, et al.
Publicado: (2022)

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
por: Adamson, Carly, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_582lg4t2ven0jrdll76mne7bq1